Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C)
Authors:
- Xuya XiaoXXXuya Xiao
- Hemalkumar B. MehtaHMHemalkumar B. Mehta
- National Covid Cohort Collaborative (N3C) ConsortiumNCNational Covid Cohort Collaborative (N3C) Consortium
- 21 August 2023
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (12) , 1251-1261
Abstract
Study Objective: To estimate the prevalence of potential moderate to severe drug–drug interactions (DDIs) involving nirmatrelvir/ritonavir, identify interacting medications, and evaluate risk factors associated with potential DDIs. Design: Cross‐sectional study. Data Source: Electronic health records from the National COVID Cohort Collaborative Enclave, one of the largest COVID‐19 data resources in the United States. Patients: Outpatients aged ≥18 years and started nirmatrelvir/ritonavir between December 23, 2021 and March 31, 2022. Intervention: Nirmatrelvir/ritonavir. Measurements: The outcome is potential moderate to severe DDIs, defined as starting interacting medications reported by National Institutes of Health 30 days before or 10 days after starting nirmatrelvir/ritonavir. Main Results: Of 3214 outpatients who started nirmatrelvir/ritonavir, the mean age was 56.8 ± 17.1 years, 39.5% were male, and 65.8% were non‐Hispanic white. Overall, 521 (16.2%) were potentially exposed to at least one moderate to severe DDI, most commonly to atorvastatin (19.2% of all DDIs), hydrocodone (14.0%), or oxycodone (14.0%). After adjustment for covariates, potential DDIs were more likely among individuals who were older (odds ratio [OR] 1.16 per 10‐year increase, 95% confidence interval [CI] 1.08–1.25), male (OR 1.36, CI 1.09–1.71), smokers (OR 1.38, CI 1.10–1.73), on more co‐medications (OR 1.35, CI 1.31–1.39), and with a history of solid organ transplant (OR 3.63, CI 2.05–6.45). Conclusions: One in six of individuals receiving nirmatrelvir/ritonavir were at risk of a potential moderate or severe DDI, underscoring the importance of clinical and pharmacy systems to mitigate such risks.Keywords
This publication has 18 references indexed in Scilit:
- Prevalence and Factors Associated with Potential Drug-Drug Interactions in Older Community-Dwelling Adults: A Prospective Cohort StudyDrugs & Aging, 2021
- Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United StatesAnnals of Internal Medicine, 2021
- The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deploymentJournal of the American Medical Informatics Association, 2020
- Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effectJournal of Antimicrobial Chemotherapy, 2020
- Graphical Depiction of Longitudinal Study Designs in Health Care DatabasesAnnals of Internal Medicine, 2019
- Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest EthiopiaSage Open Medicine, 2019
- Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011JAMA Internal Medicine, 2016
- A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensivenessJournal of Research in Pharmacy Practice, 2016
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesAnnals of Internal Medicine, 2007
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987